The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
unknown📝 Article Content
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady
📄 Summary
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady